香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失 承 擔 任 何 責 任。 Shunten International (Holdings) Limited 順騰國際（控股）有限公司 （於開曼群島註冊成立之有限公司） （股份代號：932） 末期業績公告 截至二零二五年三月三十一日止年度 董 事（「董 事」）會（「董事會」）公 佈 順 騰 國 際（控 股）有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）截 至 二 零 二 五 年 三 月 三 十 一 日 止 年 度 之 經 審 核 綜 合 業 績，連 同 上 個 財 政 年 度 之 比 較 數 字。本 集 團 截 至 二 零 二 五 年 三 月 三 十 一 日 止 年 度 之 經 審 核 綜 合 業 績 經 由 本 公 司 之 審 核 委 員 會（「審核委 員 會」）審 閱 ...

Financial Performance - Total revenue for the six months ended September 30, 2024, was approximately HKD 102,996,000, a decrease of 19.5% compared to HKD 128,012,000 for the same period last year[9]. - The health and beauty supplements and products business generated revenue of HKD 100,191,000, down 20.5% from HKD 126,004,000 year-on-year[9]. - The property investment business saw revenue increase by 39.7% to HKD 2,805,000 from HKD 2,008,000 in the previous year[9]. - The company reported a loss attributable to owners of HKD 4,261,000, compared to a profit of HKD 10,846,000 in the same period last year, representing a decline of 139.3%[9]. - Adjusted net profit for the period was HKD 2,739,000, down 81.4% from HKD 14,746,000 year-on-year[9]. - Gross profit for the same period was HKD 79,655,000, down 19% from HKD 98,164,000 year-over-year[58]. - Operating profit significantly decreased to HKD 706,000 from HKD 17,449,000, reflecting a decline of 95.9%[58]. - The net loss for the period was HKD 4,261,000, a substantial decline from a profit of HKD 10,799,000 in the same period last year[58]. - Basic and diluted loss per share was HKD (0.14), compared to earnings of HKD 0.35 per share in the prior year[62]. Revenue Breakdown - Total revenue decreased by approximately 19.5% from about HKD 128,012,000 to approximately HKD 102,996,000, primarily due to weak retail market and consumer sentiment in Hong Kong and Macau[25]. - Revenue from health and beauty supplements decreased by about 20.5% from approximately HKD 126,004,000 to about HKD 100,191,000, attributed to declining consumer spending and changing consumption patterns[25]. - Revenue from property investment increased by approximately 40.0% from about HKD 2,008,000 to approximately HKD 2,805,000, reflecting additional rental income from property usage changes[26]. - The group reported segment revenue of HKD 100,191,000 from health and beauty supplements and products, and HKD 2,805,000 from property investment, totaling HKD 102,996,000 for the six months ended September 30, 2024[86]. Expenses and Costs - Sales cost decreased by approximately 21.8% to about HKD 23,300,000, aligning with the revenue decline, while gross margin slightly increased by about 0.6% to approximately 77.3%[27]. - Selling and distribution expenses decreased by approximately 13.7% to about HKD 22,600,000, mainly due to prudent cost control measures on advertising and reduced sales commissions[29]. - Administrative expenses decreased by approximately 2.5% to about HKD 49,800,000, primarily due to reduced rent for designated counters in retail stores[30]. - Employee costs during the reporting period were approximately HKD 36,100,000, down from approximately HKD 38,300,000 in the same period last year[40]. Cash and Liquidity - Cash and cash equivalents increased by 47.3% to HKD 18,704,000 from HKD 12,700,000[9]. - As of September 30, 2024, the company's cash and bank balances were approximately HKD 18,700,000, an increase from approximately HKD 12,700,000 as of March 31, 2024[36]. - The net cash generated from operating activities was HKD 16,927,000, a decrease from HKD 36,260,000 in the previous year[72]. - The company reported a net increase in cash and cash equivalents of HKD 5,999,000, compared to HKD 8,295,000 in the same period last year[72]. - The company’s operating cash flow before changes in working capital was HKD 12,767,000, significantly lower than HKD 26,308,000 in the previous year[72]. Assets and Liabilities - Total assets as of September 30, 2024, were HKD 248,210,000, down from HKD 258,379,000 as of March 31, 2024[64]. - The company’s total liabilities decreased to HKD 292,798,000 from HKD 287,296,000 year-over-year[68]. - Accounts receivable as of September 30, 2024, totaled approximately HKD 25,825,000, down from HKD 27,652,000 as of March 31, 2024[100]. - Bank borrowings as of September 30, 2024, amounted to approximately HKD 121,490,000, an increase from HKD 110,965,000 as of March 31, 2024[106]. Strategic Initiatives - The company launched a new customer relationship management mobile app "御賞會" to enhance customer engagement and marketing strategies[22]. - The company plans to expand its market presence by promoting products through designated cross-border e-commerce platforms, targeting mainland Chinese customers[48]. - New products launched include "Zhongda Traditional Chinese Medicine Sensitive Patch" and upgraded versions of existing products, with further launches planned for the second half of the year[49]. - The company plans to continue expanding its product offerings and market presence, focusing on health and beauty sectors[79]. Corporate Governance - The board does not recommend declaring an interim dividend for the reporting period, consistent with the previous year[46]. - The company has complied with the corporate governance code as per the listing rules during the reporting period[139]. - All directors confirmed compliance with the standard code for securities trading during the reporting period, with no violations reported[141]. - The Audit Committee consists of three independent non-executive directors, overseeing financial reporting and internal controls[142].

Financial Performance - For the six months ended September 30, 2024, the company reported revenue of HKD 102,996,000, a decrease of 19.5% compared to HKD 128,012,000 for the same period in 2023[3] - The adjusted net profit for the period was HKD 2,739,000, down 81.5% from HKD 14,746,000 in the previous year[3] - The company incurred a loss attributable to owners of HKD 4,261,000, compared to a profit of HKD 10,846,000 in the same period last year[3] - The company reported a pre-tax loss of HKD 2,893,000 for the six months ended September 30, 2024, compared to a pre-tax profit of HKD 13,556,000 for the same period in 2023[23][28] - The company recorded a loss attributable to shareholders of approximately HKD 4.3 million, compared to a profit of approximately HKD 10.8 million in the same period last year[45] - Total revenue for the period was HKD 103 million, a decrease of approximately 19.5% from HKD 128 million in the previous year[55] Revenue Breakdown - The segment revenue from health and beauty products was HKD 100,191,000, while property investment revenue was HKD 2,805,000 for the six months ended September 30, 2024[26] - The revenue from health and beauty supplements decreased by approximately 20.5% to about HKD 100.2 million, down from HKD 126 million in the same period last year[57] - Revenue from property investment increased by approximately 40.0% to about HKD 2.8 million, compared to HKD 2 million in the previous year[57] Cost and Expenses - The cost of sales decreased by approximately 21.8% to about HKD 23.3 million, with a gross margin slightly increasing to about 77.3%[58] - Selling and distribution expenses decreased by approximately 13.7% to about HKD 22.6 million, due to cost control measures and reduced sales commissions[59] - Administrative expenses decreased by approximately 2.5% to about HKD 49.8 million, primarily due to reduced rent for designated counters[60] - The company's employee costs decreased to HKD 36.07 million from HKD 38.27 million, a reduction of about 5.7%[32] - The company’s inventory costs decreased to HKD 16.9 million from HKD 22.48 million, a decline of approximately 25.0%[32] Assets and Liabilities - Total assets decreased to HKD 248,210,000 from HKD 258,379,000 as of March 31, 2024[12] - The company’s accounts receivable as of September 30, 2024, was approximately HKD 25.83 million, down from HKD 27.65 million as of March 31, 2024[40] - The company’s accounts payable as of September 30, 2024, was approximately HKD 1.84 million, a decrease from HKD 2.36 million as of March 31, 2024[42] - The total liabilities as of September 30, 2024, were HKD 164,303,000, a decrease from HKD 172,726,000 as of March 31, 2024, reflecting a reduction of about 4.9%[30] - The net current liabilities improved to HKD (73,745,000) from HKD (79,545,000) year-on-year[12] Cash Flow and Liquidity - The company's cash and cash equivalents increased to HKD 18,704,000 from HKD 12,700,000[12] - As of September 30, 2024, the cash and bank balance was approximately HKD 18.7 million, up from HKD 12.7 million as of March 31, 2024[66] - Current liabilities decreased to HKD 157,240,000 from HKD 165,500,000, indicating improved liquidity[12] Strategic Initiatives - The company launched a customer relationship management mobile app "御賞會" to enhance customer engagement and marketing strategies[52] - The company is expanding sales channels by opening flagship stores on Tmall and Douyin to enter the mainland China market[50] - The group plans to actively explore new revenue sources and expand sales channels to enhance market share in the health and beauty supplement sector[78] - The group aims to leverage cross-border e-commerce platforms to reach mainland Chinese customers, utilizing social media and key opinion leaders for product promotion[78] Future Outlook - The company continues to adopt the going concern basis in preparing its financial statements, indicating confidence in its operational sustainability in the foreseeable future[1] - The company will continue to monitor market conditions and implement appropriate strategies to optimize overall performance[46] Dividend Policy - The company did not recommend the payment of an interim dividend for the two interim periods[36] - The board does not recommend declaring an interim dividend for the reporting period, consistent with the previous year[77] Other Information - The company applied several amendments to the Hong Kong Financial Reporting Standards, which did not significantly impact the financial position or performance for the current and prior periods[18] - There were no significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[71] - The overall capital management strategy remains unchanged, focusing on optimizing debt and equity balance to maximize shareholder returns[69] - The group has no significant contingent liabilities as of September 30, 2024, consistent with the previous reporting period[75]

Revenue and Profitability - Revenue from health and beauty supplements increased by 6.8% to HK$230,580,000 in 2024 from HK$215,920,000 in 2023[10] - Property investment revenue surged by 2,318.4% to HK$5,006,000 in 2024 from HK$207,000 in 2023[10] - Total revenue for continuing operations rose by 9.0% to HK$235,586,000 in 2024 compared to HK$216,127,000 in 2023[10] - Gross profit increased by 10.8% to HK$184,212,000 in 2024, with a gross profit margin of 78.2%[10] - Profit attributable to owners of the Company decreased by 98.6% to HK$571,000 in 2024 from HK$41,036,000 in 2023[10] - Adjusted Net Profit fell by 37.3% to HK$15,571,000 in 2024 from HK$24,847,000 in 2023[10] - The Group's total revenue for the Reporting Period reached HK$235.6 million, representing a year-on-year increase of 9.0% from HK$216.1 million[26] - The Group's revenue increased by approximately 9.0% to approximately HK$235.6 million for the Reporting Period, compared to approximately HK$216.1 million for the year ended 31 March 2023[42] Financial Position - Cash and cash equivalents decreased by 3.1% to HK$12,700,000 in 2024 from HK$13,108,000 in 2023[10] - Net assets increased by 19.7% to HK$171,608,000 in 2024 from HK$143,410,000 in 2023[10] - Total equity attributable to owners of the Company rose by 18.4% to HK$172,887,000 in 2024 from HK$146,007,000 in 2023[10] - Net assets per share increased by 20.0% to HK$0.06 in 2024 from HK$0.05 in 2023[10] - The Group's cash and bank balances were approximately HK$12.7 million, a slight decrease from HK$13.1 million in 2023, with a current ratio of approximately 0.5 times[86][90] - The gearing ratio improved to approximately 79.8% from 111.3% in 2023, indicating a reduction in total borrowings relative to equity[86][90] - As of March 31, 2024, the Group had secured bank borrowings of approximately HK$111.0 million, an increase from HK$61.7 million in 2023[119][124] Operational Performance - The Group's healthcare business in Hong Kong experienced steady growth due to increased demand following the reopening of borders and government initiatives[26] - Despite the recovery in the Hong Kong retail market, challenges such as rising global interest rates and increased operating costs have pressured pricing strategies and profit margins[27] - The Group is investing in research and development to introduce a diverse range of new healthcare products to meet evolving market demands[28] - Total visitor arrivals in Hong Kong increased by 715% to approximately 40,814,000 during the Reporting Period, compared to 5,008,000 for the year ended 31 March 2023[43] - Overall retail sales in Hong Kong recorded a growth of 9.6% for the Reporting Period compared to the year ended 31 March 2023, indicating a gradual recovery in the retail industry[45] Marketing and Customer Engagement - A flagship store on Tmall was established in June 2024 to tap into the mainland China market, with plans for an e-shop on Douyin[33] - A dedicated customer loyalty membership program mobile application was launched in June 2024 to enhance customer engagement and service experience[34] - The Group has intensified marketing efforts through social media and television advertisements to improve brand awareness and image[50] - The Group increased its special designated counters from 55 to 61 in Hong Kong and Macau as of 31 March 2024, aiming to enhance customer shopping experiences[51] Research and Development - The Royal Medic Research and Development Centre will continue to support the development of new products and improve existing ones to maintain competitive advantage[35] - The Group's research and development center, Yuyitang, will continue to support the development of new products to maintain a competitive edge in quality and innovation[38] - The Royal Medic Research and Development Centre is focused on improving quality control standards and developing new products to meet evolving customer demands[108] Cost Management - Selling and distribution expenses rose by 15.0% to approximately HK$54.5 million, primarily due to increased commission expenses[67] - Administrative expenses increased by 21.7% to approximately HK$103.8 million, mainly due to higher rent from designated counters[68] - The cost of sales increased by approximately HK$1.6 million or 3.2% to approximately HK$51.4 million, with a stable gross profit margin of 78.2%[65] - The Group plans to implement effective measures to control administration and production costs in response to economic challenges[128][129] Governance and Management - The company has a strong governance structure with independent non-executive directors serving on various committees, enhancing oversight and accountability[140][143] - The management team is composed of professionals with diverse backgrounds in finance, compliance, and business management, ensuring strategic leadership[144][148] - The board includes members with significant experience in both local and international markets, contributing to informed decision-making and strategic direction[139][140][143] Future Outlook and Strategy - The Group aims to capture new business opportunities arising from the gradual recovery of the retail market to enhance long-term shareholder value[109] - The Group is committed to enhancing operational efficiency and market responsiveness in the health and beauty supplements industry through optimized internal workflows and effective marketing strategies[101] - The Group aims to diversify its business by rolling out new products and expanding distribution channels to enhance overall performance[128][129] Risks and Compliance - The Group is exposed to foreign exchange risks primarily from transactions in US dollars and Renminbi, and management will continue to monitor and manage this exposure[118] - The Group is closely monitoring regulatory changes in the health supplement industry, which may significantly impact future development if compliance is not maintained[121][126] - The Group does not currently have a hedging policy for foreign exchange risks, primarily exposed to USD and RMB[123] Share Options and Dividends - The Board does not recommend the payment of a final dividend for the year ended 31 March 2024, consistent with the previous year where no dividend was paid[170] - As of 31 March 2024, there were no share options granted, exercised, cancelled, lapsed, or outstanding under both the 2013 and 2023 Share Option Schemes[185] - The purpose of the 2023 Share Option Scheme is to grant share options to eligible participants as incentives or rewards for their contributions[200]

Financial Performance - Revenue for the year ended March 31, 2024, increased to HKD 235,586,000, up 9.0% from HKD 216,127,000 in the previous year[4] - Adjusted net profit for the year was HKD 15,571,000, a decrease of 37.4% compared to HKD 24,847,000 in the prior year[5] - Gross profit rose to HKD 184,212,000, representing a 10.7% increase from HKD 166,310,000 year-on-year[4] - The company reported a net profit attributable to shareholders of HKD 571,000, a significant decline from HKD 41,036,000 in the previous year[4] - Basic and diluted earnings per share from continuing operations were HKD 0.02, down from HKD 1.33 in the previous year[11] - The segment performance for health and beauty supplements showed a profit of HKD 52,140, down from HKD 69,555 in the previous year, indicating a decline of about 25%[31] - The pre-tax profit for continuing operations was HKD 4,574, a decrease from HKD 43,766 in the previous year, indicating a decline of about 89%[31] - The profit attributable to the company's owners was approximately HKD 600,000, a significant decrease from HKD 41 million in the previous year[58] - Adjusted net profit for the year was approximately HKD 15.6 million, down from HKD 24.8 million in the previous year[58] Revenue Breakdown - Revenue from health and beauty supplements and products was HKD 230,580,000, while property investment revenue was HKD 5,006,000 for the year ended March 31, 2024[24] - The company confirmed revenue upon transfer of control of goods to customers, typically at the point of delivery, with a return policy affecting variable consideration[26] - The property investment revenue is recognized over time as rental income is accrued from operating leases[27] - The company's revenue from health and beauty supplements increased by approximately 6.8% from about HKD 215.9 million in the previous year to approximately HKD 230.6 million in the current reporting period[66] - Revenue from property investment surged 24 times from approximately HKD 200,000 to about HKD 5 million, primarily due to full-year rental income from a newly acquired property[67] Assets and Liabilities - Total assets as of March 31, 2024, were HKD 258,379,000, up from HKD 242,366,000 in the previous year[13] - Non-current assets increased to HKD 258,379,000, primarily driven by the rise in investment properties[13] - The company’s equity attributable to shareholders rose to HKD 172,887,000 from HKD 146,007,000 in the previous year[14] - Total assets for the reporting segments increased to HKD 318,915 from HKD 293,946, reflecting a growth of approximately 8.5%[33] - The total liabilities for the reporting segments decreased to HKD 92,729 from HKD 105,215, a reduction of about 12%[33] - Accounts receivable decreased from HKD 41.4 million to HKD 29.1 million, reflecting a reduction of approximately 29.7%[49] - The total amount of accounts payable decreased from HKD 24.6 million to HKD 21.1 million, a decline of approximately 14.2%[56] Cash Flow and Financing - The company’s cash and cash equivalents decreased to HKD 12,700,000 from HKD 13,108,000 year-on-year[13] - The group’s cash and bank balances as of March 31, 2024, were approximately HKD 12,700,000, slightly down from HKD 13,100,000 in 2023, with a current ratio of about 0.5 times[81] - The group held unutilized general bank financing of approximately HKD 40,000,000 as of March 31, 2024, up from HKD 20,000,000 in 2023[81] - The company incurred financing costs of HKD 7,777, an increase from HKD 4,968, representing a rise of about 56%[39] - Financing costs rose to approximately HKD 7.8 million from HKD 5 million, attributed to new bank loans and interest payable to a shareholder[75] - As of March 31, 2024, the group held secured bank borrowings of approximately HKD 111 million, an increase from HKD 61.7 million in 2023[96] Operational Changes - The company ceased operations of its e-commerce promotion business through Advance Rider Limited as of August 30, 2022, focusing on health and beauty supplements and property investment[29] - The company plans to expand its sales channels, having increased the number of designated counters from 55 to 61 in Hong Kong and Macau[62] - The company will continue to enhance its marketing strategy, including social media promotions and television advertisements, to improve brand image and awareness[62] - The group plans to expand its business through cross-border e-commerce platforms, having officially opened a flagship store on Tmall in June 2024[86] - A new customer relationship management system and a mobile application for loyal customers were launched in June 2024 to enhance digital service experiences[87] - The R&D center in Hong Kong Science Park is focused on improving product quality control and developing new products to meet changing customer demands[89] Market and Economic Conditions - The number of visitors to Hong Kong surged by 715% to approximately 40.8 million during the reporting period, compared to 5 million in the previous year[59] - The overall retail sales in Hong Kong grew by 9.6% during the reporting period, indicating a gradual recovery in the retail sector[59] - Economic downturns may significantly affect consumer preferences and spending, prompting the group to implement cost control measures and diversify its product offerings[100] Governance and Compliance - The company has adopted corporate governance practices in line with the applicable codes and has complied with all relevant regulations during the reporting period[105] - The audit committee has reviewed the consolidated financial statements and confirmed that they were prepared in accordance with applicable accounting standards[107] Dividends - The company did not declare or recommend any dividends for the year ending March 31, 2024[44] - The board did not recommend a final dividend for the reporting period, consistent with the previous year[102] Other Information - The financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards, with no significant impact from the new standards implemented during the year[18] - There were no significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[90] - There have been no significant events occurring after the reporting period up to the date of this announcement[97] - The annual report and notice of the 2024 annual general meeting will be published in accordance with listing rules at the appropriate time[110]

Financial Performance - Revenue for the six months ended September 30, 2023, was HKD 128,012,000, an increase of 14% compared to HKD 112,294,000 for the same period in 2022[9] - Gross profit for the same period was HKD 98,164,000, up from HKD 86,111,000, reflecting a gross margin improvement[9] - Profit from continuing operations for the six months was HKD 10,799,000, a decrease of 43% from HKD 18,932,000 in the previous year[9] - Total comprehensive income for the period was HKD 30,202,000, compared to HKD 18,224,000 in the prior year, indicating a significant increase[11] - Basic and diluted earnings per share from continuing operations were both HKD 0.35, down from HKD 0.61 in the previous year[13] - The company reported a profit of HKD 10,846,000 during the period, contributing to the overall increase in equity[18] - For the six months ended September 30, 2023, the company reported a profit of HKD 10,846,000, a decrease of 42.4% compared to HKD 18,735,000 for the same period in 2022[41] Expenses and Liabilities - Administrative expenses increased to HKD 50,863,000 from HKD 39,367,000, reflecting a rise of approximately 29%[9] - The company reported a loss of HKD 50,000 from the sale of a subsidiary, compared to a loss of HKD 237,000 in the previous year[9] - Other income and losses included a loss of HKD 3,611,000, contrasting with a gain of HKD 3,462,000 in the prior year[9] - The company did not report any profit from associates during the current period, compared to a profit of HKD 6,000 in the previous year[9] - The total liabilities of the company as of September 30, 2023, were not disclosed in the provided documents, but the financial position indicates a need for careful monitoring of expenses and revenue growth strategies moving forward[4] Assets and Cash Flow - As of September 30, 2023, total assets amounted to HKD 264,491,000, an increase from HKD 242,366,000 as of March 31, 2023, representing a growth of approximately 9.3%[15] - The company's cash and cash equivalents increased to HKD 21,195,000 from HKD 13,108,000, marking a significant rise of 61.5%[20] - Net current liabilities improved to HKD (82,443,000) from HKD (94,875,000), indicating a reduction in liabilities by approximately 13.1%[15] - Operating cash flow before changes in working capital was HKD 26,308,000, down from HKD 33,736,000, a decrease of approximately 22.1%[20] - The company reported a net cash inflow from operating activities of HKD 36,260,000, compared to HKD 8,777,000 in the previous year, representing a substantial increase of 312.5%[21] Equity and Borrowings - The total equity attributable to owners of the company rose to HKD 176,257,000 from HKD 146,007,000, an increase of approximately 20.7%[18] - The company raised HKD 50,000,000 in new bank borrowings during the period, indicating a strategy to enhance liquidity[21] - As of September 30, 2023, the company had total bank and other borrowings of HKD 110,912,000, an increase from HKD 79,737,000 as of March 31, 2023[56] - The company repaid approximately HKD 18,825,000 of bank and other borrowings during the six months ended September 30, 2023, compared to HKD 11,985,000 for the same period in 2022[56] Market and Strategic Initiatives - The group is optimistic about the growth momentum in the consumer health market and plans to expand into new markets outside of Hong Kong, particularly in mainland China and other Asian regions[84] - The group is enhancing its internal management systems to improve cost efficiency, logistics management, and procurement cycles[85] - The group has appointed a well-known singer as the spokesperson for its new NMN product, aiming to attract a wider customer base across different age groups[87] - The group is closely monitoring regulatory changes in the health supplement industry to adapt its business strategies accordingly[90] - The company's health and beauty supplement business is closely tied to the economic environment in Hong Kong, with potential impacts on consumer preferences and spending due to economic slowdown or recession[91] - The company aims to launch more new products and expand distribution channels to diversify its business and enhance overall performance[91] Corporate Governance and Compliance - The company has complied with all applicable corporate governance codes as per the listing rules during the reporting period[107] - The audit committee, consisting of three independent non-executive directors, has reviewed the interim financial statements for the period[110] - The company has disclosed related party transactions in its interim report, with certain transactions exempt from disclosure requirements under listing rules[100] - The company has appointed new directors and executives, including a non-executive director and a deputy CEO, effective from September 25, 2023[102] Shareholder Information - As of September 30, 2023, the company had a total of 3,107,893,440 shares issued, with significant shareholdings disclosed[93] - Mr. Zhang Shaohui holds 723,242,000 shares, representing 23.27% of the company's issued share capital[93] - Leading Virtue Holdings Limited, controlled by Mr. Zhang, also holds 723,242,000 shares, indicating a strong ownership concentration[98] - Ms. Liang Lishan holds 718,804,033 shares, representing 23.13% of the company's issued share capital, indicating another significant shareholder[98] Share Option Plan - The board of directors has been granted options to purchase shares under a stock option plan adopted on September 13, 2023[97] - The company has adopted a new share option plan effective from September 27, 2023, replacing the previous plan from 2013, which was terminated[103] - As of September 30, 2023, the maximum number of share options available under the new plan is 310,789,344 shares, representing 10% of the company's issued shares[105] - No share options were granted, exercised, cancelled, or lapsed under the 2013 share option plan during the six months ending September 30, 2023[105]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shunten International (Holdings) Limited 順騰國際（控股）有限公司 （於開曼群島註冊成立之有限公司） （股份代號：932） 中期業績公告 截至二零二三年九月三十日止六個月 財務摘要 截至九月三十日止六個月 二零二三年 二零二二年 千港元 千港元 （未經審核） （未經審核） 持續經營業務： 收益 128,012 112,294 毛利 98,164 86,111 ...

Financial Performance - Revenue for the year ended March 31, 2023, increased to HK$216,127,000, up 38.8% from HK$155,639,000 in 2022[11]. - Gross profit for the same period rose to HK$166,310,000, representing a 55% increase compared to HK$107,309,000 in 2022[11]. - Profit attributable to owners of the Company for the year was HK$41,036,000, a significant recovery from a loss of HK$43,888,000 in the previous year[11]. - Revenue from continuing operations increased to approximately HK$216.1 million, representing a growth of approximately HK$60.5 million or 38.9% compared to the previous year[40]. - The gross profit margin for continuing operations improved to approximately 76.9%, an increase of about 8% from the previous year's margin of 68.9%[41]. - The Group recorded a profit attributable to owners of approximately HK$41.0 million for the year ended 31 March 2023, compared to a loss of approximately HK$43.9 million for the previous year[39]. Assets and Equity - Total assets as of March 31, 2023, were HK$339,446,000, an increase of 37.4% from HK$246,773,000 in 2022[11]. - Shareholders' equity increased to HK$146,007,000, up 38.9% from HK$105,159,000 in 2022[11]. - As of March 31, 2023, the Group's cash and bank balances were approximately HK$13.1 million, down from HK$35.3 million in the previous year[47]. - The current ratio remained stable at approximately 0.5 times as of March 31, 2023, consistent with the previous year[47]. - The gearing ratio improved to approximately 111.3% as of March 31, 2023, compared to 115.9% in the previous year[47]. - The Group had unutilised general banking facilities of approximately HK$20 million as of March 31, 2023, significantly up from HK$1.0 million in the previous year[47]. Market Expansion and Strategy - The Company plans to continue expanding its market presence and developing new products and technologies in the upcoming fiscal year[11]. - The Group plans to explore the Mainland China and Southeast Asian markets to expand its operational presence and bring "Royal Medic" to new potential markets[35]. - The Group has developed a new business segment focused on corporate sales to diversify its revenue streams and reduce operational risks[35]. - The Group is actively expanding its markets in other Asian regions, including Mainland China, Singapore, and Malaysia, to generate additional income in the coming financial years[62]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[102]. - Market expansion plans include entering two new international markets by Q3 2024, aiming for a 10% market share within the first year[102]. Marketing and Brand Development - The brand "Royal Medic" has established a strong local sentiment and brand value, enabling it to recover sales momentum post-pandemic[20]. - The Group's marketing strategies included increased advertising in the Mainland prior to the border reopening, aiming for high brand penetration[29]. - The appointment of Mr. Hins Cheung as the "20th Anniversary Ambassador" is expected to enhance brand recognition among younger consumers[27]. - The Group has launched a series of advertising and marketing campaigns to promote the Royal Medic brand, aiming to attract new customers globally[65]. - The average age of healthcare product consumers has decreased to around 30 years old, prompting the Group to recruit younger management to better connect with this demographic[26]. Operational Efficiency and Cost Management - The Group has streamlined its cost structure, effectively controlling operating costs and achieving satisfying operating results during the year[22]. - The Group plans to implement effective measures to control administration and production costs while continuing to roll out new products and expand distribution channels[85]. - The company has achieved a 30% reduction in operational costs through efficiency improvements over the past year[102]. - The Group plans to invest in and develop an internal management system to enhance cost effectiveness and operational efficiency[64]. Human Resources and Management - Employee costs for the Reporting Period were approximately HK$67.6 million, an increase from HK$56.2 million in the previous year, with the number of employees rising to 276[49]. - The company has established a competitive remuneration package to attract and retain employees, including salaries, discretionary bonuses, and training opportunities[56]. - The management team includes experienced professionals with backgrounds in both public and private sectors, enhancing the company's strategic capabilities[110]. - The company is committed to continuous improvement in its operational strategies and market expansion initiatives[110]. Compliance and Governance - The company has a strong focus on compliance, overseen by Mr. Tsang Chi Wai Rock, who has over 30 years of experience in the accounting and finance sector[112]. - The company aims to enhance its corporate governance and compliance functions, led by a team with extensive qualifications and experience[115]. - The company has adopted the Model Code for securities transactions by directors, and all directors confirmed compliance throughout the year ended March 31, 2023[185]. - The company confirmed the independence of all current independent non-executive directors for the year ended March 31, 2023[168]. Future Outlook - The Group is optimistic about sales growth for the coming financial years due to the end of COVID-related restrictions and increased consumer spending in Hong Kong[61]. - The company is investing in R&D for new technologies, with a budget allocation of $5 million for the upcoming year[102]. - A new product line is set to launch in Q2 2024, expected to contribute an additional $3 million in revenue[102]. - The company plans to enhance shareholder returns with a proposed dividend increase of 10% in the next fiscal year[102].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shunten International (Holdings) Limited 順騰國際（控股）有限公司 （於開曼群島註冊成立之有限公司） （股份代號：932） 末期業績公告 截至二零二三年三月三十一日止年度 財務概要 二零二三年 二零二二年 千港元 千港元 （經重列） 持續經營業務 收益 216,127 155,639 毛利 166,310 107,309 ...

Financial Performance - Revenue for the six months ended September 30, 2022, was HKD 112,294,000, representing an increase of 23.3% compared to HKD 91,047,000 for the same period in 2021[9] - Gross profit for the same period was HKD 86,111,000, up 40.5% from HKD 61,306,000 year-on-year[9] - The profit from continuing operations for the six months was HKD 26,543,000, compared to a loss of HKD 46,107,000 in the previous year[9] - The total comprehensive income for the period was HKD 18,224,000, a significant recovery from a loss of HKD 58,239,000 in the prior year[11] - Basic earnings per share from continuing operations was HKD 0.61, compared to a loss of HKD 2.11 in the same period last year[13] - The company reported a profit of HKD 18,735,000 for the six months ended September 30, 2022, compared to a loss of HKD 57,868,000 in the same period last year[52] - The basic earnings per share from continuing operations for the current period is HKD 0.0061, while the previous year's loss per share was HKD 0.0211[54] Cost Management - The company reported a decrease in selling and distribution expenses to HKD 18,917,000 from HKD 16,505,000, reflecting a strategic focus on cost management[9] - Administrative expenses decreased slightly to HKD 39,367,000 from HKD 40,618,000, indicating improved operational efficiency[9] - The company incurred employee costs of HKD 32,717,000 for the current period, an increase of 14% from HKD 28,716,000 in the previous year[33] - Employee costs for the reporting period were approximately HKD 33.8 million, compared to HKD 29.9 million in the same period last year, reflecting an increase in workforce expenses[94] Asset and Liability Management - As of September 30, 2022, total non-current assets amounted to HKD 99,316 thousand, a decrease of 41.2% from HKD 168,790 thousand as of March 31, 2022[15] - Current assets increased to HKD 130,108 thousand, up 66.5% from HKD 77,983 thousand as of March 31, 2022[15] - Net current assets improved to HKD 21,801 thousand, compared to a net current liability of HKD 65,832 thousand as of March 31, 2022[15] - The company’s total liabilities decreased to HKD 108,307 thousand from HKD 143,815 thousand as of March 31, 2022[15] - The company’s total assets less current liabilities stood at HKD 121,117 thousand, an increase from HKD 102,958 thousand as of March 31, 2022[15] - The company reported a net cash inflow from investing activities of HKD 53,192 thousand, compared to HKD 4,942 thousand in the previous year[23] Cash Flow - Cash and cash equivalents rose significantly to HKD 61,680 thousand, an increase of 74.8% from HKD 35,276 thousand as of March 31, 2022[15] - Operating cash flow before changes in working capital was HKD 33,736 thousand, compared to HKD 15,224 thousand in the previous year[21] - Cash generated from operating activities was HKD 10,655 thousand, slightly down from HKD 11,832 thousand in the previous year[21] - The current ratio improved to approximately 1.2 times as of September 30, 2022, compared to 0.5 times as of March 31, 2022[92] Market Strategy and Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[11] - The management remains optimistic about future performance, citing a strong recovery in demand and operational improvements[11] - The company plans to launch over 20 stock-keeping units (SKUs) covering three main product lines in 2022, in collaboration with several pharmaceutical entities and university research centers[103] - The company aims to diversify its business and expand distribution channels by launching more new products to enhance overall performance[107] Regulatory and Economic Environment - The company has identified significant regulatory risks that may impact the health supplement and food industry in Hong Kong due to potential changes in policies and laws regarding traditional Chinese medicine ingredients[106] - The company is closely monitoring the economic environment and plans to implement effective measures to control administrative and production costs in response to economic challenges[107] Shareholder Information - As of September 30, 2022, Mr. Zhang Shaohui holds 723,242,000 shares, representing 23.27% of the issued share capital[113] - Mr. Chen Yande holds 733,568,000 shares, representing 23.60% of the issued share capital[119] - The total issued share capital of the company as of September 30, 2022, is 3,107,893,440 shares[119] Corporate Governance - The company has complied with all applicable corporate governance code provisions as of September 30, 2022, except for a deviation regarding the roles of the chairman and CEO from April 1, 2021, to May 18, 2022[140] - The Audit Committee consists of three independent non-executive directors, ensuring compliance with financial reporting and risk management standards[145] - The interim financial information for the period 2022/2023 was reviewed by external auditors in accordance with Hong Kong standards[145] Management Changes - Mr. Lai resigned as an executive director effective July 1, 2022, and Mr. Lin was appointed as the sole CEO effective September 3, 2022[125] - Mr. Yang was appointed as Chief Operating Officer effective September 14, 2022, after resigning from his independent non-executive director role[128] - The company has undergone several changes in its board of directors, including the appointment and resignation of various members throughout 2022[125][128]